This Week’s Biotech Highlights
This week in biotech was all about the wisdom of the crowds:
The crowd comprising Canada’s Natural Resources Committee, including Conservative MPs, in order to maintain our domestic capability to produce isotopes for medical imaging and treatment.
The crowd of VenGrowth investors spoke clearly in favour of the funds’ deal with Covington, approving the transaction by a wide margin on 4 of the 5 votes, according to the Financial Post.
The crowd of recent biotech IPOs, however, is telling us that we are still in a challenging environment for the public markets. Anacor, Zealand and Zogenix , lowering their . . . [more]
